Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 5
2022 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H, Moretti L, Kilburn LS, Johnson H, Macpherson IR, Ring A, Bliss JM, Hou Y, Toy W, Katzenellenbogen JA, Chandarlapaty S, Turner NC. Kingston B, et al. Cancer Discov. 2024 Feb 8;14(2):274-289. doi: 10.1158/2159-8290.CD-22-1387. Cancer Discov. 2024. PMID: 37982575 Free PMC article.
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance.
Strillacci A, Sansone P, Rajasekhar VK, Turkekul M, Boyko V, Meng F, Houck-Loomis B, Brown D, Berger MF, Hendrickson RC, Chang Q, de Stanchina E, Pareja F, Reis-Filho JS, Rajappachetty RS, Del Priore I, Liu B, Cai Y, Penson A, Mastroleo C, Berishaj M, Borsetti F, Spisni E, Lyden D, Chandarlapaty S, Bromberg J. Strillacci A, et al. NPJ Breast Cancer. 2022 Aug 23;8(1):96. doi: 10.1038/s41523-022-00470-6. NPJ Breast Cancer. 2022. PMID: 35999225 Free PMC article.
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Rosen EY, Won HH, Zheng Y, Cocco E, Selcuklu D, Gong Y, Friedman ND, de Bruijn I, Sumer O, Bielski CM, Savin C, Bourque C, Falcon C, Clarke N, Jing X, Meng F, Zimel C, Shifman S, Kittane S, Wu F, Ladanyi M, Ebata K, Kherani J, Brandhuber BJ, Fagin J, Sherman EJ, Rekhtman N, Berger MF, Scaltriti M, Hyman DM, Taylor BS, Drilon A. Rosen EY, et al. Nat Commun. 2022 Mar 18;13(1):1450. doi: 10.1038/s41467-022-28848-x. Nat Commun. 2022. PMID: 35304457 Free PMC article.
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. Smith AE, et al. Nat Commun. 2021 Nov 18;12(1):6667. doi: 10.1038/s41467-021-27093-y. Nat Commun. 2021. PMID: 34795269 Free PMC article.
Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.
Hitchman TD, Bayshtok G, Ceraudo E, Moore AR, Lee C, Jia R, Wang N, Pachai MR, Shoushtari AN, Francis JH, Guan Y, Chen J, Chang MT, Taylor BS, Sakmar TP, Huber T, Chi P, Chen Y. Hitchman TD, et al. Clin Cancer Res. 2021 Mar 1;27(5):1476-1490. doi: 10.1158/1078-0432.CCR-20-2860. Epub 2020 Nov 23. Clin Cancer Res. 2021. PMID: 33229459 Free PMC article.
Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.
Liu B, Liu Z, Chen S, Ki M, Erickson C, Reis-Filho JS, Durham BH, Chang Q, de Stanchina E, Sun Y, Rabadan R, Abdel-Wahab O, Chandarlapaty S. Liu B, et al. J Clin Invest. 2021 Jan 4;131(1):e138315. doi: 10.1172/JCI138315. J Clin Invest. 2021. PMID: 33031100 Free PMC article.
Discovery through clinical sequencing in oncology.
Donoghue MTA, Schram AM, Hyman DM, Taylor BS. Donoghue MTA, et al. Nat Cancer. 2020 Aug;1(8):774-783. doi: 10.1038/s43018-020-0100-0. Epub 2020 Aug 10. Nat Cancer. 2020. PMID: 35122052 Free PMC article. Review.
12 results